CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.

about

Emerging Treatment Models in Rheumatology: IgG4-Related Disease: Insights Into Human Immunology and Targeted Therapies.The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis.Dichotomous roles of co-stimulatory molecules in diabetes mellitus.

P2860

Q39346488-D76032DC-2D06-471E-BA53-E5ECBCB384A5 Q45804014-3BF0702B-2521-4DB0-A0CA-8EE3668C7669 Q49519207-7A7B387D-6750-42AA-87CC-F021F3DA6FE0

P2860

CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.

Item

http://www.wikidata.org/entity/Q38672568

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.

@en

type

Item

label

CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.

@en

prefLabel

CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.

@en

P1476

CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.

@en

P2093

Alberto Sulli

http://www.w3.org/2001/XMLSchema#string

Carmen Pizzorni

http://www.w3.org/2001/XMLSchema#string

Sabrina Paolino

http://www.w3.org/2001/XMLSchema#string

P2860

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The pathogenesis of rheumatoid arthritis

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.

CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production.

Abatacept treatment for rheumatoid arthritis

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.

Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig.

P304

417-425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/1744666X.2016.1133295

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maurizio Cutolo

P577

2015-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26679631

http://www.w3.org/2001/XMLSchema#string

CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.

about

P2860

P2860

CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698